Scripps Research expands drug repurposing efforts for COVID-19

By The Science Advisory Board staff writers

April 16, 2020 -- Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.

Researchers from Scripps' drug development division Calibr will work with scientists from around the world to look for compounds from individual drugs or drug combinations that could treat patients with COVID-19. It is part of an accelerator launched by the Bill & Melinda Gates Foundation to develop COVID‑19 therapeutics.

Scripps Research
Scripps Research's ReFRAME drug repurposing collection. Image courtesy of Scripps Research.

ReFrame's collection includes 14,000 compounds, including medications already repurposed for disease treatment. Calibr created the collection in 2018 to address tropical diseases and other unmet medical needs.

The jury is still out for SARS-CoV-2 intermediate host
Scientists have been searching for the intermediate host between bats, which are known to carry coronaviruses, and the first introduction of SARS-CoV-2...
BioInformatics releases more results from COVID-19 lab tracker survey
Scientists whose labs have been closed due to the COVID-19 pandemic are spending their time writing and planning future research projects, according to...
Chicago's McCormick Place to house COVID-19 patients
The McCormick Place convention center in Chicago is being converted into an alternate care facility that can house up to 3,000 patients with COVID-19.
COVID-19 research consortium expands
The EndPandemic National Data Consortium is about to expand by six life sciences and information technology companies.
New COVID-19 R&D initiatives announced
A series of new initiatives aims to simplify scientific literature discovery and acquisition during the COVID-19 crisis, according to Research Solutions....

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter